Amlitelimab exhibited clinically meaningful efficacy over 24 weeks in the treatment of adults with moderate to severe atopic dermatitis, according to study results presented at the European Academy of Dermatology and Venereology 2023 Congress.
The positive results from the phase 2b STREAM-AD study also demonstrated an acceptable safety profile for amlitelimab (Sanofi), a fully human non-depleting monoclonal antibody.
“The data presented at EADV provide more detailed insight into amlitelimab’s potential as a best-in-class therapy for people with atopic dermatitis,” Naimish